The Patent Finder
WP

Woolsey Pharmaceuticals, Inc.

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

11 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2041
Next term end
8
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 6, 2026
    The maintenance fee for Methods of Treating Cortical Dementia Associated Wandering (US 11,666,583) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
  • 2 fees due Apr 3 to 10, 2027 · next Apr 3
  • 1 fee due Jul 9, 2027
    The maintenance fee for Methods of Treating Agitation and Other Dementia-Associated Behavioral Symptoms (US 11,865,119) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
  • 1 fee due Oct 2, 2027
    The maintenance fee for Oral Formulations of Fasudil with Ion Exchange Resin (US 11,944,633) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,311,553Methods of Treating 4-Repeat Tauopathies
In force
 · High confidence
In forceHigh confidence
US 11,642,352Methods of Treating Wandering in Lewy Body Dementia
In force
 · High confidence
In forceHigh confidence
US 11,666,583Methods of Treating Cortical Dementia Associated Wandering
In force
 · High confidence
In forceHigh confidence
US 11,771,704Methods of Using Rho Kinase Inhibitors to Treat Alzheimer's Disease
In force
 · High confidence
In forceHigh confidence
US 12,329,761Methods of Using Rho Kinase Inhibitors to Treat Alzheimer's Disease
In force
 · High confidence
In forceHigh confidence
US 12,290,522Method of Treating Amyotrophic Lateral Sclerosis
In force
 · Medium confidence
In forceMedium confidence
US 11,779,588Method of Treating Amyotrophic Lateral Sclerosis
In force
 · High confidence
In forceHigh confidence
US 11,865,119Methods of Treating Agitation and Other Dementia-Associated Behavioral Symptoms
In force
 · High confidence
In forceHigh confidence
US 11,944,633Oral Formulations of Fasudil with Ion Exchange Resin
In force
 · High confidence
In forceHigh confidence
US 12,115,167Oral Formulations of Fasudil with Ion Exchange Resin
In force
 · Low confidence
In forceLow confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 22 applications pending · 11 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited